How much funding has Alnara raised?

Alnara has raised $55.0M in total funding, most recently a Series B round.

Who are Alnara's investors?

Alnara's investors include Bessemer VP, Third Rock Ventures, Frazier Healthcare.

Where is Alnara headquartered?

Alnara is headquartered in Cambridge, Massachusetts, United States.

Alnara

Closed

Cambridge, United States · Founded 2008 · $55.0M raised

Biotech

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2008
Business Model: B2B

Website: alnara.com
Total Funding: $55.0M
Last Round: $35.0M Series BJan 2009
Rounds: 2

About

Alnara Pharmaceuticals, Inc. was a Cambridge, Massachusetts-based biotechnology company dedicated to developing and commercializing novel protein therapeutics for the treatment of metabolic diseases. Co-founded in 2008 by Alexey Margolin, Rich Aldrich, and Christoph Westphal, Alnara's innovative approach focused on designing effective protein therapies that could be orally delivered directly to the gastrointestinal tract without systemic absorption. The company's lead product, liprotamase, was a non-porcine pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis and chronic pancreatitis, which completed Phase 3 clinical trials. Alnara was backed by Third Rock Ventures, Frazier Healthcare, MPM Capital, Bessemer Venture Partners, and Longwood Founders Fund, and was acquired by Eli Lilly and Company in 2010.

Summary

Alnara is a Biotech company based in Cambridge, United States, founded in 2008. It has raised $55.0M in total across 2 rounds, most recently a $35.0M Series B round in Jan 2009. Investors include Bessemer VP, Third Rock Ventures and Frazier Healthcare.